As summarized by Stier, Vos, and Kenley in 2013, the pre-specified primary endpoint for statistically significant weight change across the dose range and study duration was not met, while the compound's tolerability profile remained comparable to placebo
BPC-157 is often discussed around localized tissue and gut-related repair models, while TB-500 is often discussed around broader tissue remodeling and thymosin beta-4 pathways
Supplied as lyophilised powder for controlled experimental preparation
Specific binding studies indicate that silent agonists stabilize certain receptor conformations favorable for interaction with endogenous neurotransmitters, potentially leading to more nuanced control of receptor activity [79, 80]
Researchers should follow their institutions storage protocols and consult the product storage guidance where applicable
As far as tested athletes are concerned - BPC is not currently on the WADA banned list under the section naming peptide hormones, growth factors, related substances, and mimetics (as of October 2020)